Browse Case Studies by
Case Studies in
- Corporate Governance
- Corporate Social Responsibility
- Economics
- Entrepreneurship
- Finance, Accounting & Control
- Leadership
- Marketing
- Organisational Behaviour / HRM
- Social Entrepreneurship
- Strategy
- All Case Studies »
Concept wise Case Studies
- Mergers, Acquisitions and Alliances - Vol. I
- Mergers, Acquisitions and Alliances - Vol. II
- Mergers, Acquisitions and Alliances - Vol. III
- Mergers, Acquisitions and Alliances - Vol. IV
- Airline Industry
- » All Concept wise Cases
Industry wise Case Studies
- Banking and Financing Services
- Retailing
- Energy and Utilities
- Oil and Gas Refining, Marketing and Distribution
- Commercial Aircraft Manufacturing
- » All Industry wise Cases
Region wise Case Studies
Mergers, Acquisitions, Alliances and Synergies Case Study
Case Title:
Daiichi’s Acquisition of Ranbaxy
Publication Month and Year : Feb 2009
Authors: Bhaskar Mutyala and K Sarat Verma
Industry: Pharmaceuticals
Region: Global
Case Code: MAA0185
Teaching Note: Available
Structured Assignment: Not Available
Abstract:
On June 11th 2008 Japan’s third largest drug maker Daiichi Sankyo announced, its strategic deal to acquire majority stake in the Indian generic drug major, Ranbaxy Laboratories Limited. Daiichi agreed to pay around US$4.2 billion for acquiring 51% stake (including promoter stake of 34.83%) in Ranbaxy, putting the total enterprise value of Ranbaxy at US$8.5 billion. Daiichi-Ranbaxy deal was the largest acquisition in the Indian pharmaceutical industry and was viewed by analysts as a step towards the consolidation in the world generic drug market.
The deal made Daiichi-Ranbaxy, the combined entity the 15th largest pharmaceutical company in the world with a market capitalization of around US$30 billion. It helped Daiichi leverage its innovative drug making capabilities and R&D expertise with Ranbaxy’s low cost manufacturing abilities to achieve a competitive position in the world generic drug market.
Some industry experts’ claimed that the price Daiichi paid for acquisition was quite high compared to the present pricing of other Indian generic drug making companies.
Pedagogical Objectives:
- An in-depth knowledge about DCF valuation techniques
- The rationale behind the acquisition of Ranbaxy by Daiichi
- Long-term synergies arising for Ranbaxy after Daiichi acquired it
- The advantages and disadvantages of M&A deals
- The need for growth through acquisitions in foreign countries
- The consolidation trends in the Indian and Global Pharma Industries.
Keywords : Mergers and Acquisitions, DCf Valuation, Pharmaceuticals Industries, Generic Drugs, Synergies, Strategy, Industry value Chain, Daiichi Sankyo, Ranbaxy, Competitive Anaysis, Open Offer, Financial Forecasting
Related Case Studies
- » Growth Strategies of Ranbaxy
- » Ranbaxy Laboratories: The Winning Chemistry
- » Ranbaxy's Acquisition of Terapia: Creation of the Largest Generic Company of Romania
- » Ranbaxy’s Sell-off to Daiichi – Rise of a New Business Model in Global Pharma?
- » Hospira’s Acquisition of Mayne Pharma: Creation of World’s Leading Generic Injectable Pharmaceutical Company